“…The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 41.3 Ci/mmol, was from DuPont NEN (I.L.C., Lisboa, Portugal); desipramine hydrochloride, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine (SCH 58261), S-(4-Nitrobenzyl)-6-thioinosine (NBTI) and 5-Iodotubericidin (ITU), (8R)-3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1], [3]diazepin-8-ol (pentostatin), α,β-methylene ADP, N6-cyclopentyladenosine (CPA), 2-p–(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine hydrochloride (CGS 21680) were purchased from Sigma-Aldrich (Sintra, Portugal). The following antibodies were used: rabbit polyclonal anti-A1 (epitope corresponding to amino acids 287-326 mapping at the C-terminus of human adenosine A 1 receptors; sc-28995), anti-A 2A (epitope corresponding to amino acids 331-412 mapping at the C-terminus of human adenosine A 2A receptors; sc-13937) were purchased from Santa Cruz Biotechnology, Inc., CA, USA; mouse monoclonal anti-tyrosine hydroxilase antibody (TH(45): sc-136100, Santa Cruz Biotechnology, Inc., CA, USA and MAB318, Millipore Corporation, CA, USA); anti-glial fribillary acidic protein (GFAP) mouse monoclonal antibody (G6171, Sigma-Aldrich, Inc., USA) and rabbit GFAP polyclonal antibody (18-0063, Invitrogen, Life Technologies, SA, Madrid, Spain).…”